R&D Pipeline
R&D Pipeline (In-House)
As of November 2024
Generic Name / Development Code |
Expected Indications | Category | Development Stage | Development Classification |
CG0070 | Non-muscle-invasive bladder cancer | Oncolytic Viral Therapy | Phase III | In-licensed / CG Oncology (U.S.) |
Linzagolix |
Uterine fibroids | GnRH receptor antagonist | NDA preparation | Kissei |
Endometriosis | Phase II | Kissei | ||
KDT-3594 | Parkinson's disease | Dopamine receptor agonist | Phase II | Kissei |
KSP-0243 | Ulcerative colitis | Phase II | Kissei |
Rovatirelin (spinocerebellar degeneration): Under consideration on the possibility of conducting additional clinical trials
R&D Pipeline (Out-Licensing)
As of November 2024
Generic Name | Expected Indications | Category | Countries & Regions | Development Company | Development Stage |
Linzagolix | Uterine fibroids | GnRH receptor antagonist | Australia | Theramex (U.K.) | NDA |
Taiwan | Synmosa Biopharma (Taiwan) | NDA | |||
Endometriosis | EU | Theramex (U.K.) | NDA | ||
Fostamatinib | Chronic idiopathic thrombocytopenic purpura | Tyrosine kinase inhibitor | Korea | JW Pharmaceutical (Korea) | NDA |
Silodosin | Dysuria associated with benign prostatic hyperplasia | Alpha 1A adrenergic receptor antagonist | Vietnam, etc. | Eisai (Japan) | NDA |